Tesamorelin Research Overview

An overview of tesamorelin, a synthetic growth hormone-releasing hormone analogue, and its research applications.

Scientific background / literature overview only. Discussion of published research does not describe the intended use of Novex Peptide products.

Novex Peptide Research Team30 July 2026 7 min read

tesamorelin GHRH growth hormone IGF-1 lipodystrophy

Introduction

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) consisting of the full 44-amino acid sequence of human GHRH with a trans-3-hexenoyl modification at the N-terminus. This modification increases its stability and duration of action compared to endogenous GHRH.

Mechanism of Action

GHRH Receptor Agonism

Tesamorelin binds to and activates the GHRH receptor in the anterior pituitary, stimulating the release of endogenous growth hormone in a pulsatile manner.

Pulsatile GH Release

Unlike direct GH administration, tesamorelin preserves the natural pulsatile pattern of GH release, which is considered physiologically more relevant in research settings.

IGF-1 Mediation

Released growth hormone acts on the liver to produce insulin-like growth factor 1 (IGF-1), which mediates many of the anabolic and metabolic effects studied in research.

Current Research

Body Composition Research

Tesamorelin has been studied in clinical trials for its effects on visceral adipose tissue, particularly in the context of HIV-associated lipodystrophy. Published data show reductions in visceral fat over 26 weeks.

Metabolic Research

Research has investigated tesamorelin's effects on lipid profiles, glucose metabolism, and cardiovascular risk markers.

Cognitive Research

Some studies have explored potential effects of tesamorelin on cognitive function, though this area remains preliminary.

Chemical Properties

**Sequence:** Trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2

**Molecular weight:** 5,135.8 Da

**Modification:** N-terminal trans-3-hexenoyl group, C-terminal amidation

Storage Considerations

Store lyophilised tesamorelin at -20°C.

Protect from light and moisture.

Reconstituted solutions should be used immediately or aliquoted and frozen.

Testing Methods

Tesamorelin batches should be verified by:

RP-HPLC for purity (≥98% recommended)

Mass spectrometry for identity confirmation

Research Limitations

Tesamorelin is supplied for in vitro laboratory research and animal model studies only. While tesamorelin has been investigated in clinical trials, findings are experimental and not established clinical facts. No medical, therapeutic, or dosing claims are made. Tesamorelin is not approved for human therapeutic use outside of its licensed indication.

References

1.Fallo F, et al. Tesamorelin and Visceral Adiposity. J Clin Endocrinol Metab. 2010;95(7):3303-3310.
2.Makimura H, et al. Tesamorelin Reduces Visceral Fat. AIDS. 2010;24(13):2091-2099.
3.Gertler A, et al. GHRH Analogues. Endocr Rev. 2014;35(5):747-775.

Research use only. This article is for educational purposes only and does not constitute advice for any application involving human use. No medical claims are made.